2026-08-05T16:12:46Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/202332024-11-28T17:41:58Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16961col_20.500.12105_16967
Repisalud author Laguno, M author Von Wichmann, MA author Van den Eynde, E author Navarro, J author Cifuentes Luna, Carmen author Murillas Angoiti, Javier author Veloso, S author Martinez-Rebollar, M author Guardiola, JM author Jou, A author Gomez-Sirvent, J. L author Cervantes, M author Pineda, JA author Lopez-Calvo, S author Carrero, A author Montes, ML author Deig, Elisabeth author Tapiz, A author Ruiz-Mesa, JD author Cruceta, A author de Lazzari, Ellsa author Mallolas, J 2024-07-09T09:12:59Z 2024-07-09T09:12:59Z 2016-12 Laguno M, Von Wichmann MA, Van Den Eynde E, Navarro J, Cifuentes Luna C, Murillas Angoiti J, et al. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study. Int J Infect Dis. 2016 Dec;53:46-51. Epub 2016 Nov 1. 10.1016/j.ijid.2016.10.028 1878-3511 1201-9712 International Journal of Infectious Diseases http://hdl.handle.net/20.500.13003/17296 27815225 L613310152 2-s2.0-84997050481 http://hdl.handle.net/20.500.12105/20233 389516700011 Introduction: Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC + pegylated interferon-alpha 2a/ribavirin (PEG-IFN/RBV) in the retreatment of HIV-HCV co-infected patients with HCV genotype 1. Methods: This was a phase III prospective trial. HIV-HCV (genotype 1) co-infected patients from 16 hospitals in Spain were included. These patients received 4 weeks of PEG-IFN/RBV (lead-in), followed by response-guided therapy with PEG-IFN/RBV plus BOC (a fixed 44 weeks was indicated in the case of cirrhosis). The primary endpoint was the sustained virological response (SVR) rate at 24 weeks post-treatment. Efficacy and safety were evaluated in all patients who received at least one dose of the study drug. Results: From June 2013 to April 2014, 102 patients were enrolled, 98 of whom received at least one treatment dose. Seventy-three percent were male, 34% were cirrhotic, 23% had IL28b CC, 65% had genotype 1a, and 41% were previous null responders. The overall SVR rate was 67%. Previous null-responders and cirrhotic patients had lower SVR rates (57% and 51%, respectively). Seventy-six patients (78%) completed the therapy scheme; the most common reasons for discontinuation were lack of response at week 12 (12 patients) and adverse events (six patients). Conclusions: Response-guided therapy with BOC in combination with PEG-IFN/RBV led to an overall SVR rate of 67%, but an SVR rate of only 51% in patients with cirrhosis. The therapy was generally well tolerated. Although the current standards of care do not include BOC + PEG-IFN/RBV, the authors believe that this combination can be beneficial in situations where new HCV direct antiviral agent interferonfree therapies are not available yet. eng PEG-IFN/RBV plus BOC therapy HIV-HCV experienced patients HCV genotype 1 Re-treatment Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study research article